The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer

Molecular Cell

Volumn 58, Issue 4, 2015, Pages 690-698

  Krogan, Nevanb J ^a,b,c,d   Lippman, Scott ^e,f   Agard, David A ^a,b   Ashworth, Alan ^b,d   Ideker, Trey ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR;

CANCER CELL; CARCINOGENESIS; DNA SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN GENOME; LIVER CANCER; OROPHARYNX CANCER; POINT MUTATION; REVIEW; SOMATIC MUTATION; TUMOR GENE; UTERINE CERVIX CANCER; BIOLOGICAL MODEL; GENE REGULATORY NETWORK; GENETICS; MUTATION; NEOPLASMS; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION;

GENE REGULATORY NETWORKS; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, GENETIC; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84929692173     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.05.008     Document Type: Review

References (119)

1. Amabile G., Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol. Med. 2009, 15:59-68.
2. Amundadottir L., Kraft P., Stolzenberg-Solomon R.Z., Fuchs C.S., Petersen G.M., Arslan A.A., Bueno-de-Mesquita H.B., Gross M., Helzlsouer K., Jacobs E.J., et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 2009, 41:986-990.
3. Ashworth A., Lord C.J., Reis-Filho J.S. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
4. Bandyopadhyay S., Kelley R., Krogan N.J., Ideker T. Functional maps of protein complexes from quantitative genetic interaction data. PLoS Comput. Biol. 2008, 4:e1000065.
5. Bandyopadhyay S., Mehta M., Kuo D., Sung M.K., Chuang R., Jaehnig E.J., Bodenmiller B., Licon K., Copeland W., Shales M., et al. Rewiring of genetic networks in response to DNA damage. Science 2010, 330:1385-1389.
6. Baranzini S.E., Galwey N.W., Wang J., Khankhanian P., Lindberg R., Pelletier D., Wu W., Uitdehaag B.M., Kappos L., Polman C.H., et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 2009, 18:2078-2090. GeneMSA Consortium.
7. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
8. Bassik M.C., Kampmann M., Lebbink R.J., Wang S., Hein M.Y., Poser I., Weibezahn J., Horlbeck M.A., Chen S., Mann M., et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 2013, 152:909-922.
9. Battle A., Jonikas M.C., Walter P., Weissman J.S., Koller D. Automated identification of pathways from quantitative genetic interaction data. Mol. Syst. Biol. 2010, 6:379.
10. Beltrao P., Cagney G., Krogan N.J. Quantitative genetic interactions reveal biological modularity. Cell 2010, 141:739-745.
11. Beyer A., Bandyopadhyay S., Ideker T. Integrating physical and genetic maps: from genomes to interaction networks. Nat. Rev. Genet. 2007, 8:699-710.
12. Bisson N., James D.A., Ivosev G., Tate S.A., Bonner R., Taylor L., Pawson T. Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor. Nat. Biotechnol. 2011, 29:653-658.
13. Braberg H., Jin H., Moehle E.A., Chan Y.A., Wang S., Shales M., Benschop J.J., Morris J.H., Qiu C., Hu F., et al. From structure to systems: high-resolution, quantitative genetic analysis of RNA polymerase II. Cell 2013, 154:775-788.
14. Califano A., Butte A.J., Friend S., Ideker T., Schadt E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 2012, 44:841-847.
15. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
16. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
17. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Research Network.
18. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
19. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Research Network.
20. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N.Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
21. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45:1113-1120. Cancer Genome Atlas Research Network.
22. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202-209. Cancer Genome Atlas Research Network.
23. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159:676-690. Cancer Genome Atlas Research Network.
24. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., Sulman E.P., Anne S.L., Doetsch F., Colman H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
25. Chang C.Q., Yesupriya A., Rowell J.L., Pimentel C.B., Clyne M., Gwinn M., Khoury M.J., Wulf A., Schully S.D. A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes. Eur. J. Hum. Genet. 2014, 22:402-408.
26. Chuang H.Y., Lee E., Liu Y.T., Lee D., Ideker T. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 2007, 3:140.
27. Chuang H.Y., Rassenti L., Salcedo M., Licon K., Kohlmann A., Haferlach T., Foà R., Ideker T., Kipps T.J. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 2012, 120:2639-2649.
28. Ciriello G., Cerami E., Sander C., Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012, 22:398-406.
29. Collins S.R., Miller K.M., Maas N.L., Roguev A., Fillingham J., Chu C.S., Schuldiner M., Gebbia M., Recht J., Shales M., et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810.
30. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., Greninger P., Brown R.D., Godfrey J.T., Cohoon T.J., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
31. Davis Z.H., Verschueren E., Jang G.M., Kleffman K., Johnson J.R., Park J., Von Dollen J., Maher M.C., Johnson T., Newton W., et al. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Mol. Cell 2015, 57:349-360.
32. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
33. Doudna J.A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346:1258096.
34. Dutkowski J., Ideker T. Protein networks as logic functions in development and cancer. PLoS Comput. Biol. 2011, 7:e1002180.
35. Fehringer G., Liu G., Briollais L., Brennan P., Amos C.I., Spitz M.R., Bickeböller H., Wichmann H.E., Risch A., Hung R.J. Comparison of pathway analysis approaches using lung cancer GWAS data sets. PLoS ONE 2012, 7:e31816.
36. Fischer B., Sandmann T., Horn T., Billmann M., Chaudhary V., Huber W., Boutros M. A map of directional genetic interactions in a metazoan cell. eLife 2015, 4. 10.7554/eLife.05464.
37. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 2013, 108:479-485.
38. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
39. Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., Ding M., Bamford S., Cole C., Ward S., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43(Database issue):D805-D811.
40. Gao F., Foat B.C., Bussemaker H.J. Defining transcriptional networks through integrative modeling of mRNA expression and transcription factor binding data. BMC Bioinformatics 2004, 5:31.
41. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
42. Giordano T.J. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159:676-690. Cancer Genome Atlas Research Network.
43. Girotti M.R., Lopes F., Preece N., Niculescu-Duvaz D., Zambon A., Davies L., Whittaker S., Saturno G., Viros A., Pedersen M., et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 2015, 27:85-96.
44. Goldstein D.B. Common genetic variation and human traits. N.Engl. J. Med. 2009, 360:1696-1698.
45. Griffith M., Griffith O.L., Coffman A.C., Weible J.V., McMichael J.F., Spies N.C., Koval J., Das I., Callaway M.B., Eldred J.M., et al. DGIdb: mining the druggable genome. Nat. Methods 2013, 10:1209-1210.
46. Gross A.M., Orosco R.K., Shen J.P., Egloff A.M., Carter H., Hofree M., Choueiri M., Coffey C.S., Lippman S.M., Hayes D.N., et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat. Genet. 2014, 46:939-943.
47. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
48. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
49. Hannum G., Srivas R., Guénolé A., van Attikum H., Krogan N.J., Karp R.M., Ideker T. Genome-wide association data reveal a global map of genetic interactions among protein complexes. PLoS Genet. 2009, 5:e1000782.
50. Hofree M., Shen J.P., Carter H., Gross A., Ideker T. Network-based stratification of tumor mutations. Nat. Methods 2013, 10:1108-1115.
51. Hudson T.J., Anderson W., Artez A., Barker A.D., Bell C., Bernabé R.R., Bhan M.K., Calvo F., Eerola I., Gerhard D.S., et al. International network of cancer genome projects. Nature 2010, 464:993-998. International Cancer Genome Consortium.
52. Ideker T., Krogan N.J. Differential network biology. Mol. Syst. Biol. 2012, 8:565.
53. Ideker T., Dutkowski J., Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell 2011, 144:860-863.
54. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am. J. Hum. Genet. 2013, 92:854-865. International Multiple Sclerosis Genetics Consortium.
55. Jäger S., Cimermancic P., Gulbahce N., Johnson J.R., McGovern K.E., Clarke S.C., Shales M., Mercenne G., Pache L., Li K., et al. Global landscape of HIV-human protein complexes. Nature 2012, 481:365-370.
56. Jäger S., Kim D.Y., Hultquist J.F., Shindo K., LaRue R.S., Kwon E., Li M., Anderson B.D., Yen L., Stanley D., et al. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 2012, 481:371-375.
57. Jerby-Arnon L., Pfetzer N., Waldman Y.Y., McGarry L., James D., Shanks E., Seashore-Ludlow B., Weinstock A., Geiger T., Clemons P.A., et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 2014, 158:1199-1209.
58. Jia P., Zheng S., Long J., Zheng W., Zhao Z. dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks. Bioinformatics 2011, 27:95-102.
59. Jones D.T., Jäger N., Kool M., Zichner T., Hutter B., Sultan M., Cho Y.J., Pugh T.J., Hovestadt V., Stütz A.M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
60. Kelley R., Ideker T. Systematic interpretation of genetic interactions using protein networks. Nat. Biotechnol. 2005, 23:561-566.
61. Koster R., Mitra N., D'Andrea K., Vardhanabhuti S., Chung C.C., Wang Z., Loren Erickson R., Vaughn D.J., Litchfield K., Rahman N., et al. Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. Hum. Mol. Genet. 2014, 23:6061-6068.
62. Kuchenbaecker K.B., Ramus S.J., Tyrer J., Lee A., Shen H.C., Beesley J., Lawrenson K., McGuffog L., Healey S., Lee J.M., et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat. Genet. 2015, 47:164-171. EMBRACE, GEMO Study CollaboratorsGEMO Study Collaborators, Breast Cancer Family RegistryBreast Cancer Family Registry, HEBONHEBON, KConFab InvestigatorsKConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators)Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study GroupAustralian Ovarian Cancer Study Group, Consortium of Investigators of Modifiers of BRCA1 and BRCA2Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
63. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921. International Human Genome Sequencing Consortium.
64. Laufer C., Fischer B., Billmann M., Huber W., Boutros M. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat. Methods 2013, 10:427-431.
65. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
66. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
67. Lee I., Blom U.M., Wang P.I., Shim J.E., Marcotte E.M. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res. 2011, 21:1109-1121.
68. Leiserson M.D., Vandin F., Wu H., Dobson J.R., Eldridge J.V., Thomas J.L., Papoutsaki A., Kim Y., Niu B., McLellan M., et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 2015, 47:106-114.
69. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847.
70. Li X., Mooney P., Zheng S., Booth C.R., Braunfeld M.B., Gubbens S., Agard D.A., Cheng Y. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods 2013, 10:584-590.
71. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N.Engl. J. Med. 2014, 371:1877-1888.
72. Longo D.L. Tumor heterogeneity and personalized medicine. N.Engl. J. Med. 2012, 366:956-957.
73. Maher B. Personal genomes: The case of the missing heritability. Nature 2008, 456:18-21.
74. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
75. Mardis E.R. The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med. 2014, 6:22.
76. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010, 11:781-789.
77. Morrison C., Smith G.C., Stingl L., Jackson S.P., Wagner E.F., Wang Z.-Q. Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat. Genet. 1997, 17:479-482.
78. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl 3). S3/1-10.
79. Nijhawan D., Zack T.I., Ren Y., Strickland M.R., Lamothe R., Schumacher S.E., Tsherniak A., Besche H.C., Rosenbluh J., Shehata S., et al. Cancer vulnerabilities unveiled by genomic loss. Cell 2012, 150:842-854.
80. Nijman S.M., Friend S.H. Cancer. Potential of the synthetic lethality principle. Science 2013, 342:809-811.
81. Novarino G., Fenstermaker A.G., Zaki M.S., Hofree M., Silhavy J.L., Heiberg A.D., Abdellateef M., Rosti B., Scott E., Mansour L., et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014, 343:506-511.
82. O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P., Levy R., Ko A., Lee C., Smith J.D., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 485:246-250.
83. Parikshak N.N., Luo R., Zhang A., Won H., Lowe J.K., Chandran V., Horvath S., Geschwind D.H. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 2013, 155:1008-1021.
84. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., Ripke S., Brumme C.J., Pulit S.L., Carrington M., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557. International HIV Controllers Study.
85. Perry J.A., Kiezun A., Tonzi P., Van Allen E.M., Carter S.L., Baca S.C., Cowley G.S., Bhatt A.S., Rheinbay E., Pedamallu C.S., et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc. Natl. Acad. Sci. USA 2014, 111:E5564-E5573.
86. Pharoah P.D., Tsai Y.-Y., Ramus S.J., Phelan C.M., Goode E.L., Lawrenson K., Buckley M., Fridley B.L., Tyrer J.P., Shen H., et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet. 2013, 45:362-370, e1-e2. Australian Cancer Study, Australian Ovarian Cancer Study GroupAustralian Ovarian Cancer Study Group.
87. Pujana M.A., Han J.-D.J., Starita L.M., Stevens K.N., Tewari M., Ahn J.S., Rennert G., Moreno V., Kirchhoff T., Gold B., et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 2007, 39:1338-1349.
88. Ramage H.R., Kumar G.R., Verschueren E., Johnson J.R., Von Dollen J., Johnson T., Newton B., Shah P., Horner J., Krogan N.J., Ott M. A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol. Cell 2015, 57:329-340.
89. Roguev A., Bandyopadhyay S., Zofall M., Zhang K., Fischer T., Collins S.R., Qu H., Shales M., Park H.O., Hayles J., et al. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. Science 2008, 322:405-410.
90. Roguev A., Talbot D., Negri G.L., Shales M., Cagney G., Bandyopadhyay S., Panning B., Krogan N.J. Quantitative genetic-interaction mapping in mammalian cells. Nat. Methods 2013, 10:432-437.
91. Sahni N., Yi S., Zhong Q., Jailkhani N., Charloteaux B., Cusick M.E., Vidal M. Edgotype: a fundamental link between genotype and phenotype. Curr. Opin. Genet. Dev. 2013, 23:649-657.
92. Sahni N., Yi S., Taipale M., Fuxman Bass J.I., Coulombe-Huntington J., Yang F., Peng J., Weile J., Karras G.I., Wang Y., et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 2015, 161:647-660.
93. Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
94. Schuldiner M., Collins S.R., Thompson N.J., Denic V., Bhamidipati A., Punna T., Ihmels J., Andrews B., Boone C., Greenblatt J.F., et al. Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. Cell 2005, 123:507-519.
95. Shen P.S., Park J., Qin Y., Li X., Parsawar K., Larson M.H., Cox J., Cheng Y., Lambowitz A.M., Weissman J.S., et al. Protein synthesis. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains. Science 2015, 347:75-78.
96. St Onge R.P., Mani R., Oh J., Proctor M., Fung E., Davis R.W., Nislow C., Roth F.P., Giaever G. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat. Genet. 2007, 39:199-206.
97. Tang H., Wei P., Duell E.J., Risch H.A., Olson S.H., Bueno-de-Mesquita H.B., Gallinger S., Holly E.A., Petersen G., Bracci P.M., et al. Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. Carcinogenesis 2014, 35:1039-1045.
98. Taylor I.W., Linding R., Warde-Farley D., Liu Y., Pesquita C., Faria D., Bull S., Pawson T., Morris Q., Wrana J.L. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 2009, 27:199-204.
99. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., Stylianou I.M., Koseki M., Pirruccello J.P., Ripatti S., Chasman D.I., Willer C.J., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
100. Turnbull C., Ahmed S., Morrison J., Pernet D., Renwick A., Maranian M., Seal S., Ghoussaini M., Hines S., Healey C.S., et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 2010, 42:504-507. Breast Cancer Susceptibility Collaboration (UK).
101. Vaske C.J., Benz S.C., Sanborn J.Z., Earl D., Szeto C., Zhu J., Haussler D., Stuart J.M. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010, 26:i237-i245.
102. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
103. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
104. Vijai J., Wang Z., Berndt S.I., Skibola C.F., Slager S.L., de Sanjose S., Melbye M., Glimelius B., Bracci P.M., Conde L. A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat. Commun. 2015, 6. 10.1038/ncomms6751.
105. Visscher P.M., Brown M.A., McCarthy M.I., Yang J. Five years of GWAS discovery. Am. J. Hum. Genet. 2012, 90:7-24.
106. Vizeacoumar F.J., Arnold R., Vizeacoumar F.S., Chandrashekhar M., Buzina A., Young J.T., Kwan J.H., Sayad A., Mero P., Lawo S., et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol. Syst. Biol. 2013, 9:696.
107. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
108. Wang K., Li M., Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat. Rev. Genet. 2010, 11:843-854.
109. Watson I.R., Takahashi K., Futreal P.A., Chin L. Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14:703-718.
110. Welter D., MacArthur J., Morales J., Burdett T., Hall P., Junkins H., Klemm A., Flicek P., Manolio T., Hindorff L., Parkinson H. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014, 42(Database issue):D1001-D1006.
111. Wilks, C., Cline, M.S., Weiler, E., Diehkans, M., Craft, B., Martin, C., Murphy, D., Pierce, H., Black, J., Nelson, D., etal. (2014). The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database: the journal of biological databases and curation.
112. Willsey A.J., Sanders S.J., Li M., Dong S., Tebbenkamp A.T., Muhle R.A., Reilly S.K., Lin L., Fertuzinhos S., Miller J.A., et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 2013, 155:997-1007.
113. Yaffe M.B. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. Sci. Signal. 2013, 6:pe13.
114. Yamanaka S. A fresh look at iPS cells. Cell 2009, 137:13-17.
115. Yang W., Soares J., Greninger P., Edelman E.J., Lightfoot H., Forbes S., Bindal N., Beare D., Smith J.A., Thompson I.R., et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41(Database issue):D955-D961.
116. Yeager M., Chatterjee N., Ciampa J., Jacobs K.B., Gonzalez-Bosquet J., Hayes R.B., Kraft P., Wacholder S., Orr N., Berndt S., et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat. Genet. 2009, 41:1055-1057.
117. Zhang J., Fujimoto J., Zhang J., Wedge D.C., Song X., Zhang J., Seth S., Chow C.W., Cao Y., Gumbs C., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346:256-259.
118. Zhu J., Zhang B., Smith E.N., Drees B., Brem R.B., Kruglyak L., Bumgarner R.E., Schadt E.E. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet. 2008, 40:854-861.
119. Zuk O., Hechter E., Sunyaev S.R., Lander E.S. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. USA 2012, 109:1193-1198.